Q-omics provides the consensus-scored NPEPPS profile across patient tissues and cancer cell-line models. NPEPPS expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NPEPPS is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, NPEPPS protein abundance shows 23,030 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRP, and GBM as cancer lineages where NPEPPS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPEPPS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPEPPS survival associations across molecular data types. NPEPPS RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPEPPS RNA expression–survival associations across cancer types. High NPEPPS expression shows unfavorable associations in LIHC, BLCA and CESC, but favorable associations in COAD, BRCA and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NPEPPS RNA expression.
This table summarizes NPEPPS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NPEPPS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPEPPS shows higher tumor expression in KIRP, LIHC, LUAD, LUSC, BRCA and CHOL. The KIRP box plot shows higher NPEPPS RNA expression in tumor versus normal tissue (log2 FC = +0.788, t-test p < 0.001).
This table shows molecular features associated with NPEPPS in patient tissues and cancer cell lines. In patient samples, NPEPPS shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPEPPS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
